Urology News and Research

Latest Urology News and Research

UT Southwestern first in North Texas to use dual-console DaVinci Surgical System

Physicians at UT Southwestern Medical Center are the first in North Texas to use the newest generation surgical robot, the dual-console DaVinci Surgical System, enabling them to perform minimally invasive surgeries with even greater precision.

11 Jun 2010

Programme on surgical and medical treatment strategies for cancer

The 5th ESU Master class on medical treatment for urological cancer is organised by the European School of Urology (ESU) on 25-27 June 2010 at the Barcel- Hotel Sants in Barcelona, Spain.

11 Jun 2010

Emerging health care models and approaches discussed at 2010 Health Care Conference

Dr. Sanford J. Siegel, president and CEO of Chesapeake Urology Associates, Maryland, was a featured panelist at the 2010 Health Care Conference for health care community executives, held at the BWI Marriott in Baltimore on June 7, 2010.

10 Jun 2010

GE Global Research awarded $4M grant to optimize new nerve labeling agent and imaging system

Researchers from GE Global Research announced today that they have been awarded a four-year, $4 million grant from the National Institutes of Health, to optimize a new nerve labeling agent and imaging system. In the future, this agent could help surgeons see delicate nerve endings that are prone to damage during certain procedures, such as prostate surgery.

10 Jun 2010

Sonic hedgehog helps regenerate critical nerve that runs along prostate: Research

After men have surgery to remove a cancerous prostate gland, up to 80 percent of them will lose the ability to have an erection because of damage to a critical nerve that runs along the prostate.

9 Jun 2010

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

Astellas Pharma Inc. announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. for $4.0 billion.

9 Jun 2010

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.

9 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

Single semen test for clearance following vasectomy

Having to provide repeated semen samples following a vasectomy could soon be a thing of the past, after 96 per cent of men were given the all-clear based on a single test three months after surgery.

8 Jun 2010

Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer

The Prostate Cancer Foundation announced today that researchers at the University of Michigan Comprehensive Cancer Center have discovered the RAF oncogene that drives fatal melanomas may also drive the aggressive forms of prostate cancer in the clinic.

8 Jun 2010

Astellas Pharma completes tender offer for outstanding shares of OSI's common stock

Astellas Pharma Inc. announced today the completion of its tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc..

8 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

New molecular imaging agent improves diagnosis of recurrent prostate cancer

Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

7 Jun 2010

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

NewYork-Presbyterian Hospital is the only tri-state-area hospital listed on the 2010 U.S.News & World Report "America's Best Children's Hospitals" "Honor Roll" and one of only eight children's hospitals in the nation to be ranked in all 10 clinical specialties. NewYork-Presbyterian provides children's health services at two major centers: NewYork-Presbyterian/Morgan Stanley Children's Hospital and the Phyllis and David Komansky Center for Children's Health.

5 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

As part of a national clinical trial, UT Southwestern Medical Center researchers found little difference in effectiveness between two popular treatments for one of the most common ailments among American women: stress urinary incontinence.

4 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the fourth fiscal quarter and the full fiscal year ended March 31, 2010.

4 Jun 2010

New synthetic Petri dish harvests human embryonic stem cells

A new synthetic Petri dish coating could overcome a major challenge to the advancement of human embryonic stem cell research, say University of Michigan researchers.

3 Jun 2010

Urology News and Research

Latest Urology News and Research

UT Southwestern first in North Texas to use dual-console DaVinci Surgical System

Programme on surgical and medical treatment strategies for cancer

Emerging health care models and approaches discussed at 2010 Health Care Conference

GE Global Research awarded $4M grant to optimize new nerve labeling agent and imaging system

Sonic hedgehog helps regenerate critical nerve that runs along prostate: Research

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Single semen test for clearance following vasectomy

Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer

Astellas Pharma completes tender offer for outstanding shares of OSI's common stock

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

New molecular imaging agent improves diagnosis of recurrent prostate cancer

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

New synthetic Petri dish harvests human embryonic stem cells

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in